SEC Form 424B3 filed by Akers Biosciences Inc.
$AKER
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol "MYMD" Upon Closing, the Combined Company will focus on developing and commercializing novel immunotherapy pipeline assets, including its lead molecule MYMD-1 Recently announced plans to initiate Phase 2 trial Akers Biosciences, Inc. ("Akers") (NASDAQ:AKER) and MyMD Pharmaceuticals, Inc. ("MYMD") today announced that at Akers' special meeting of stockholders held on April 15, 2021, Akers obtained sufficient votes for each proposal required to consummate the previously announced proposed merger between Akers and MYMD. MYMD previously obtained a sufficient number of written consents fr
Akers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending health lifespan and treating immune mediated illnesses, has reached an agreement with a major medical school to conduct a Phase 2 clinical trial to investigate the effectiveness of MYMD-1 to treat immune mediated depression in patients affected with COVID-19. MYMD believes that this investigator-initiated study is the first of its kind and addresses a significant unmet medical need. In a finding published in JAMA Network Open on 3/12/21, it was found that 52% of individuals who had COVID-19 had an associa
Chaired by Katharine Whartenby, Ph.D., members include experts in molecular medicine, aging, pathology and oncology Akers Biosciences, Inc. (NASDAQ:AKER), today announced that its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, has completed the formation of its Scientific Advisory Board (SAB). The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine. "Each member of our Scientific Adviso
3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
4 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
3 - MyMD Pharmaceuticals, Inc. (0001321834) (Issuer)
S-3/A - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - MyMD Pharmaceuticals, Inc. (0001321834) (Filer)
8-K - Akers Biosciences, Inc. (0001321834) (Filer)
SC 13G/A - Akers Biosciences, Inc. (0001321834) (Subject)
SC 13G - Akers Biosciences, Inc. (0001321834) (Subject)